Literature DB >> 8081887

Effects of beta subunit cytoplasmic domain deletions on the recruitment of the integrin alpha v beta 6 to focal contacts.

R I Cone1, A Weinacker, A Chen, D Sheppard.   

Abstract

The integrin alpha v beta 6 is expressed primarily in epithelial cells and mediates attachment to the extracellular matrix protein fibronectin. We recently observed that alpha v beta 6 localizes to focal contacts when cells that express the receptor are plated on fibronectin. To determine which regions of the beta 6 cytoplasmic domain are required for recruitment to focal contacts, the wild type human beta 6 cytoplasmic domain are required for recruitment to focal contacts, the wild type human beta 6 subunit and mutants containing selective deletions within the beta 6 cytoplasmic domain were stably expressed in Chinese Hamster Ovary cells. The beta 6 cytoplasmic domain is composed of a 41 amino acid region that is highly conserved among integrin beta subunits, and a unique 11 amino acid carboxy terminal extension. The 11 amino acid extension was not required for localization to focal contacts; in fact, its removal appeared to increase receptor localization. However, removal of any of the 3 conserved regions previously identified as important for the localization of beta 1 integrins to focal contacts (Reszka, et al., 1992, J. Cell Biol. 117:1321-30) eliminated recruitment of beta 6 to focal contacts. These data suggest that, as with the integrin beta 1 subunit, multiple regions within the first 41 amino acids of the beta 6 cytoplasmic domain are necessary for recruitment of alpha v beta 6 to focal contacts. However, the unique 11 amino acid carboxy terminus of beta 6 is not required for this recruitment, and may actually play a negative regulatory role.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081887     DOI: 10.3109/15419069409004430

Source DB:  PubMed          Journal:  Cell Adhes Commun        ISSN: 1023-7046


  8 in total

1.  Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function.

Authors:  George Su; Maki Hodnett; Nanyan Wu; Amha Atakilit; Cynthia Kosinski; Mika Godzich; Xiao Zhu Huang; Jiyeun K Kim; James A Frank; Michael A Matthay; Dean Sheppard; Jean-François Pittet
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

2.  The role of endocytosis in regulating L1-mediated adhesion.

Authors:  K E Long; H Asou; M D Snider; V Lemmon
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

3.  Role of the cytoplasmic domain of the beta-subunit of integrin alpha(v)beta6 in infection by foot-and-mouth disease virus.

Authors:  L C Miller; W Blakemore; D Sheppard; A Atakilit; A M King; T Jackson
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain.

Authors:  M Agrez; A Chen; R I Cone; R Pytela; D Sheppard
Journal:  J Cell Biol       Date:  1994-10       Impact factor: 10.539

5.  Modulation of beta1A integrin functions by tyrosine residues in the beta1 cytoplasmic domain.

Authors:  T Sakai; Q Zhang; R Fässler; D F Mosher
Journal:  J Cell Biol       Date:  1998-04-20       Impact factor: 10.539

6.  Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection.

Authors:  Terry Jackson; Stuart Clark; Stephen Berryman; Alison Burman; Stephanie Cambier; Dezhi Mu; Stephen Nishimura; Andrew M Q King
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo.

Authors:  E J Filardo; P C Brooks; S L Deming; C Damsky; D A Cheresh
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

8.  Integrin alpha(v)beta6-associated ERK2 mediates MMP-9 secretion in colon cancer cells.

Authors:  X Gu; J Niu; D J Dorahy; R Scott; M V Agrez
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.